


GSK delivers strong 2025 performance and reaffirms long-term outlooks

"GSK delivered another strong performance in 2025, driven mainly by Specialty Medicines, with double-digit sales growth in Respiratory, Immunology & Inflammation (RI&I), Oncology and HIV. Good R&D progress also continued, with 5 major product approvals achieved and several acquisitions and new partnerships completed to strengthen the pipeline further in oncology and RI&I. We expect this positive momentum to continue in 2026, which will be a key year of execution and operational delivery with strong focus on commercial launches and accelerating R&D. We are well placed to move forward in this next phase for GSK - to deliver our outlooks - and to create new value for patients and shareholders."

Luke Miels
Chief Executive Officer, GSK



Specialty Medicines

£13.5bn +17%

Respiratory, Immunology and Inflammation +18%
Oncology +43%
HIV +11%

Vaccines

£9.2bn +2%

General Medicines

£10.0bn -1%

Core operating profit
£9.8bn
+11%

Total EPS
141.1p
>100%

Core EPS
172.0p
+12%

Dividend Q4
18p
FY
66p

2025

5
major FDA approvals

7
pivotal trial starts

Expected in 2026

2
new major product approvals

5
pivotal readouts

10
pivotal trial starts

2026 guidance

Turnover growth
3-5%

Core operating profit growth
7-9%

2031 sales outlook

>£40bn



Journalists/media see press release on www.gsk.com for full details on full-year and Q4 2025. Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures on pages 20-21 and 53-56 of the press release. Product group sales may not add to total sales due to rounding. References to growth are at constant exchange rates (CER) unless stated otherwise.

Ahead Together